반응식
Br[C:2]1[CH:7]=[C:6]([Cl:8])[CH:5]=[CH:4][C:3]=1[C:9]([N:11]1[CH2:16][CH2:15][N:14]([C:17]2[C:22]([CH3:23])=[CH:21][C:20]([CH3:24])=[CH:19][N:18]=2)[CH2:13][CH2:12]1)=[O:10].[C:25]([N:28]1[CH2:32][CH2:31][NH:30][C:29]1=[O:33])(=[O:27])[CH3:26]>>[C:25]([N:28]1[CH2:32][CH2:31][N:30]([C:2]2[CH:7]=[C:6]([Cl:8])[CH:5]=[CH:4][C:3]=2[C:9]([N:11]2[CH2:16][CH2:15][N:14]([C:17]3[C:22]([CH3:23])=[CH:21][C:20]([CH3:24])=[CH:19][N:18]=3)[CH2:13][CH2:12]2)=[O:10])[C:29]1=[O:33])(=[O:27])[CH3:26]참가 물질
3
실험 절차
By reaction and treatment in the same manner as in Preparation Example 12 and using (2-bromo-4-chlorophenyl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (408.7 mg) described in Preparation Example 119 and 1-acetyl-2-imidazolidinone (128 mg), the title compound (221.5 mg) was obtained.
후처리
- customBy reaction and treatment in the same manner
- customas in Preparation Example 12
출처 및 근거
- ORD 기록
- ord-d21bd3ebc0454c659f701522f20f091a
- 출처 데이터셋
- uspto-grants-2013_01
- 특허 번호
- US08354401B2
연결된 노트
불러오는 중…